![]() |
市場調查報告書
商品編碼
1884058
可吸收縫合線市場規模、佔有率、成長及全球產業分析:依類型、應用和地區劃分的洞察與預測(2024-2032)Absorbable Sutures Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032 |
||||||
2024年全球可吸收縫線市場規模為36億美元,預計2025年將成長至37.9億美元,到2032年將達到64.4億美元。北美地區在2024年佔市場主導地位,市場佔有率為41.11%,這得益於其先進的醫療基礎設施和較高的手術量。可吸收縫合線(也稱為溶解縫合線或可吸收縫合線)旨在隨著時間的推移在體內自然降解,無需取出,因此非常適合用於體內手術。這些縫合線由天然材料(例如羊腸線)或合成聚合物(例如聚二氧雜環己酮、聚乳酸-羥基乙酸共聚物和聚己內酯)製成。
市場動態:市場推動因素、阻礙因素與機會
全球外科手術數量的不斷增長是可吸收縫合線市場的主要推動因素。在美國,每年約進行130萬例膝關節置換術及76萬例髖關節置換術。全球每年約進行40萬例冠狀動脈繞道手術(CABG)。此外,人口老化導致血管成形術、關節置換術和器官移植等手術的需求日益增長,增加了對縫合線的需求。現代縫合器械的高效性也促進了其廣泛應用,並推動了市場成長。
然而,人們越來越傾向於使用其他傷口閉合方法,例如手術釘、組織黏合劑和止血劑,這在一定程度上限制了市場成長。在開放手術和骨科手術中,縫合釘被廣泛用於快速縫合傷口;而在美容和皮膚外科手術中,為了最大限度地減少疤痕,人們更傾向於使用黏合劑。這些替代方法尤其在急診手術中被優先考慮,這往往限制了可吸收縫線的應用。
縫合技術的創新正在推動市場機會。合成聚合物(例如聚乙醇酸-共-L-乳酸)(PGA-L)和二乙醯幾丁質,以及抗菌塗層(例如三氯生)的進步,提高了縫合線的抗拉強度、生物相容性和吸收性能。二乙醯幾丁質衍生縫合線的研究表明,其在14天時強度保持率為63%,在42天時完全吸收,並且組織修復速度更快,與傳統縫合線相比,可帶來更好的手術效果。
新興趨勢
無結可吸收縫線在微創手術(如骨科、心血管和腹腔鏡手術)中備受關注。這些縫合線可降低感染風險,無需拆線,並能實現一致的傷口閉合,避免了打結帶來的挑戰。研究表明,與傳統縫線相比,可吸收無結倒刺縫線在術後 60 天和 90 天可顯著降低手術部位感染率。合成生物工程縫線和抗菌塗層縫線等技術進步,以及機器人輔助手術的出現,正在進一步加速其應用。
依類型劃分,多股/編織縫合線因其在心臟和假體手術中卓越的操控性、結節安全性和靈活性,預計將在 2024 年佔市場主導地位。單絲縫合線在血管和顯微血管外科手術中也佔了相當大的市場佔有率,這主要得益於其較低的感染風險。
以縫合方式劃分,由於合成縫線可降低過敏反應的風險,預計在2024年,合成縫線將佔市場主導地位。同時,由於天然縫合線(例如羊腸線)具有高吸收性和成本效益,因此在眼科、婦科和整形外科手術中更受歡迎。
依應用領域劃分,骨科領域將在2024年引領市場,2023年美洲地區共進行了370萬例關節置換手術。婦產科也將佔較大佔有率,這主要得益於剖腹產率的上升(預計將從2020年的21%上升到2030年的29%)。心臟手術(包括兒科和先天性心臟病手術)佔第二大市場佔有率,在美國每年進行超過 4 萬例手術。其他應用,例如普通外科手術、整形外科手術和眼科手術,也推動了整體市場成長。
依最終用戶劃分,由於手術量大且報銷制度有利,醫院和門診手術中心 (ASC) 預計在 2024 年將佔市場主導地位。專科診所和其他機構,包括教學醫院和軍事醫院,也為市場成長做出了貢獻。
預計到 2024 年,北美將以 14.8 億美元的市佔率引領市場。歐洲將佔第二大市場佔有率,這主要得益於骨科手術量大。亞太地區預計將實現最快成長,這主要得益於 Healthium Medtech 的 TRUMAS 縫線等新產品的推出。整形手術將推動拉丁美洲的成長,而中東和非洲的成長將較為溫和,這主要是由於慢性病的增加。
The global absorbable sutures market was valued at USD 3.60 billion in 2024, and it is projected to grow to USD 3.79 billion in 2025, reaching USD 6.44 billion by 2032. North America dominated the market in 2024, holding a 41.11% share, driven by advanced healthcare infrastructure and high surgical volumes. Absorbable sutures, also known as dissolvable or resorbable sutures, are designed to naturally degrade in the body over time, eliminating the need for removal and making them ideal for internal surgical applications. These sutures are manufactured from natural materials such as catgut and synthetic polymers, including polydioxanone, polyglactin, and poliglecaprone.
Market Dynamics: Drivers, Restraints, and Opportunities
The rising number of surgeries globally is a major driver for absorbable sutures. In the U.S., approximately 1.3 million knee replacements and 760,000 hip replacements are performed annually. Worldwide, around 400,000 coronary artery bypass graft (CABG) surgeries are conducted each year. Moreover, the aging population requires frequent procedures such as angioplasty, joint replacements, and organ transplants, increasing suture demand. The high efficiency of modern suturing devices also contributes to broader adoption, fueling market growth.
However, the growing preference for alternative wound closure methods, such as surgical staples, tissue adhesives, and hemostats, restrains market growth. Staples, commonly used in laparotomy and orthopedic surgeries, offer rapid closure, while adhesives are favored in cosmetic and dermatological procedures to minimize scarring. These alternatives are particularly preferred in emergency interventions, limiting the adoption of absorbable sutures.
Market opportunities are driven by innovations in suture technology. Advancements in synthetic polymers, such as poly(glycolide-co-l-lactide) (PGA-L) and diacetyl chitin, along with antimicrobial coatings like Triclosan, have enhanced tensile strength, biocompatibility, and absorption profiles. Research on diacetyl chitin-derived sutures demonstrated 63% strength retention at 14 days, full absorption by 42 days, and faster tissue repair, providing improved outcomes compared to traditional sutures.
Emerging Trends
Knotless absorbable sutures are gaining traction, especially in minimally invasive surgeries such as orthopedic, cardiovascular, and laparoscopic procedures. These sutures reduce infection risk, eliminate the need for removal, and provide consistent wound closure without knot-tying challenges. Studies indicate that absorbable knotless barbed sutures significantly reduce surgical site infections at 60 and 90 days post-operation compared to conventional sutures. Technological advancements, including synthetic bioengineered and antimicrobial-coated sutures, coupled with robotic-assisted surgeries, further accelerate adoption.
By type, multifilament/braided sutures dominated in 2024 due to superior handling, knot security, and flexibility in cardiac and prosthetic surgeries. Monofilament sutures also held a substantial share, preferred in vascular and microvascular procedures due to lower infection risk.
By form, synthetic sutures dominated in 2024 due to reduced hypersensitivity reactions, while natural sutures like catgut were preferred in ophthalmic, gynecological, and plastic surgeries because of higher absorbability and cost-effectiveness.
By application, orthopedics led the market in 2024, with 3.7 million arthroplasty procedures performed in the Americas in 2023. Gynecology accounted for a significant share, supported by rising cesarean section rates, projected to increase from 21% in 2020 to 29% by 2030. Cardiology, including pediatric and congenital heart surgeries, accounted for the second-largest share, with over 40,000 surgeries performed annually in the U.S. General surgery and other applications, such as cosmetic and ophthalmic surgeries, contributed to overall market growth.
By end-user, hospitals and ambulatory surgical centers (ASCs) dominated the market in 2024 due to higher surgical volumes and favorable reimbursement. Specialty clinics and other facilities, including academic and military hospitals, also contributed to growth.
North America led the market with USD 1.48 billion in 2024. Europe held the second-largest share, driven by high orthopedic surgery volumes, while Asia Pacific is expected to grow the fastest, fueled by new product launches such as Healthium Medtech's TRUMAS sutures. Latin America's growth is driven by cosmetic procedures, while the Middle East & Africa shows moderate growth due to increasing prevalence of chronic diseases.
Competitive Landscape
Key players include Johnson & Johnson Services, Medtronic, B. Braun SE, Genesis Medtech, and Dolphin Sutures. Strategies focus on regulatory approvals, new product launches, and partnerships. Notable developments include Genesis MedTech receiving NMPA approval in China for antibacterial sutures (2023) and Orion Sutures' participation in MEDICA 2024 in Germany.
Conclusion
The absorbable sutures market, valued at USD 3.60 billion in 2024 and expected to reach USD 6.44 billion by 2032, is experiencing robust growth due to increasing surgical demand, technological innovation, and rising adoption of knotless and synthetic sutures. While alternatives like staples and adhesives pose challenges, advancements and regional expansions present significant opportunities for market players globally.
Segmentation By Type
By Form
By Application
By End-user
By Region